2. Search Result
Search Result
Results for "

STZ

" in MedChemExpress (MCE) Product Catalog:

19

Inhibitors & Agonists

2

Peptides

2

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-13753
    Streptozotocin
    Maximum Cited Publications
    39 Publications Verification

    Streptozocin; NSC-85998; U 9889

    		 DNA/RNA Synthesis DNA Alkylator/Crosslinker Autophagy Bacterial Antibiotic Apoptosis Infection Cancer
    Streptozotocin (Streptozocin) is an antibiotic widely used in experimental animal models of induced diabetes. Streptozotocin enters B cells via the glucose transporter (GLUT2) and causes the alkylation of DNA ( DNA-methylating ). Streptozotocin can induce the apoptosis of β cells .
    Streptozotocin
  • HY-N3015
    Bruceine E

    		Others Metabolic Disease
    Bruceine E is a quassinoid from seeds of Brucea javanica (L.) Merr, exhibiting hypoglycemia effect . Bruceine E exhibits blood glucose lowering effect in both nondiabetic mice and Streptozotocin (STZ)-induced diabetic rats at lower dose .
    Bruceine E
  • HY-103023
    CLP290
    1 Publications Verification

    		 Potassium Channel Neurological Disease
    CLP290 is an orally available activator of the neuron-specific K +-Cl − cotransporter KCC2, displays potential for treatment of a wide range of neurological and psychiatric indications. CLP290 can significantly lower blood arginine-vasopressin (AVP) and glucose levels in STZ rats .
    CLP290
  • HY-115910A
    Y13g dihydrochloride

    		Interleukin Related Cholinesterase (ChE) Neurological Disease
    Y13g dihydrochloride is the potent inhibitor of both AChE and IL-6. Interleukin-6 (IL-6) and acetylcholinesterase (AChE) are two important targets implicated in progression of Alzheimer's Disease (AD). Y13g dihydrochloride reverses the STZ-induced memory deficit, and shows histopathology similarly as in normal animals .
    Y13g dihydrochloride
  • HY-115910
    Y13g

    		Cholinesterase (ChE) Interleukin Related Neurological Disease
    Y13g is the potent inhibitor of both AChE and IL-6. Interleukin-6 (IL-6) and acetylcholinesterase (AChE) are two important targets implicated in progression of Alzheimer's Disease (AD). Y13g reverses the STZ-induced memory deficit, and shows histopathology similarly as in normal animals .
    Y13g
  • HY-147503
    Vin-F03

    		Apoptosis Cardiovascular Disease
    Vin-F03 is a potent pancreatic β-cells protective agent with an EC50 of 0.27 µM. Vin-F03 effectively promotes β-cell survival and protects β-cells from STZ-induced apoptosis. Vin-F03 can be used for type 2 diabetes mellitus research .
    Vin-F03
  • HY-147502
    Vin-C01

    		Apoptosis Cardiovascular Disease
    Vin-C01 is a potent pancreatic β-cells protective agent with an EC50 of 0.22 µM. Vin-C01 effectively promotes β-cell survival and protects β-cells from STZ-induced apoptosis. Vin-C01 can be used for type 2 diabetes mellitus research .
    Vin-C01
  • HY-160186
    20-SOLA

    		Others Cardiovascular Disease
    20-SOLA is the first water soluble and orally active 20-HETE antagonist. 20-SOLA greatly ameliorates changes in blood pressure and renal injury associated with a streptozotocin (STZ)-diabetic mouse model. 20-SOLA also is a GPR75 receptor blocker. 20-SOLA can be used for the research of cardiovascular pathologies .
    20-SOLA
  • HY-155961
    Antidiabetic agent 2

    		Dipeptidyl Peptidase Phosphatase Amylases Glucosidase Metabolic Disease
    Antidiabetic agent 2 (Compound 56) is a glucose-uptake promoter. Antidiabetic agent 2 inhibits DPP-4, PTP-1B, α-amylase, and α-glucosidase with IC50s of 0.036, 0.042, 0.241, 0.185 μM. Antidiabetic agent 2 decreases blood glucose levels .
    Antidiabetic agent 2
  • HY-Q40876
    BBT

    		Calcium Channel Metabolic Disease
    BBT is an enhancer of impaired glucose-stimulated insulin secretion (GSIS). BBT exhibits anti-hyperglycemia activity, and protects β-cells from cytokine- or streptozotocin (STZ)-induced cell death in type 2 diabetes models. BBT acts function via cAMP/PKA and long-lasting (L-type) voltage-dependent Ca2+ channel/CaMK2 pathway .
    BBT
  • HY-153617
    FOXO1-IN-3

    		Others Metabolic Disease
    FOXO1-IN-3 is a highly-selective and orally active FOXO1 inhibitor. FOXO1-IN-3 reduces hepatic glucose production in mice. FOXO1-IN-3 improves insulin sensitivity and glucose control in db/db mice without causing weight gain .
    FOXO1-IN-3
  • HY-P2222
    DX600

    		Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    DX600 is a selective ACE2 specific inhibitor (KD: 1.3 nM), and does not cross-react with ACE. DX600 exacerbates diabetes-induced cardiovascular dysfunction and the increase in cardiac and renal NOX activity .
    DX600
  • HY-P2222A
    DX600 TFA
    1 Publications Verification

    		 Angiotensin-converting Enzyme (ACE) Cardiovascular Disease Metabolic Disease
    DX600 TFA is a selective ACE2 specific inhibitor (KD: 1.3 nM), and does not cross-react with ACE. DX600 TFA exacerbates diabetes-induced cardiovascular dysfunction and the increase in cardiac and renal NOX activity .
    DX600 TFA
  • HY-13662
    Lansoprazole
    1 Publications Verification

    AG-1749

    		 Proton Pump Bacterial Phospholipase Inflammation/Immunology Cancer
    Lansoprazole (AG 1749) is an orally active proton pump inhibitor which prevents the stomach from producing acid. Lansoprazole (AG 1749) is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor) .
    Lansoprazole
  • HY-148922
    PPARα/γ agonist 2

    		PPAR Metabolic Disease
    PPARα/γ agonist 2 is an orally active PPARα full agonist and PPARγ partial agonist. PPARα/γ agonist 2 activates PPARα and PPARγ with EC50 values of 0.95 μM and 0.91 μM respectively. PPARα/γ agonist 2 is also a PTP1B inhibitor. PPARα/γ agonist 2 is an anti-diabetic agent .
    PPARα/γ agonist 2
  • HY-153175
    BT44

    		RET Neurological Disease
    BT44 is a selective RET activator. BT44 can penetrate through the blood-brain barrier and can be used for the research of neurodegenerative disorders and diabetes mellitus .
    BT44
  • HY-142114
    SRI-37330

    		Others Metabolic Disease
    SRI-37330 is an orally active TXNIP inhibitor. SRI-37330 decreases glucagon secretion and action and blocks hepatic glucose output. SRI-37330 can be used in the research of obesity and diabetes .
    SRI-37330
  • HY-121238
    Hyocholic Acid

    		Others Metabolic Disease
    Hyocholic Acid is a bile acid found in pig. Hyocholic Acid can also be found in urine samples from patients with cholestasis. Hyocholic Acid promotes GLP-1 secretion via activating TGR5 and inhibiting FXR in enteroendocrine cells. Hyocholic Acid is known for its exceptional resistance to type 2 diabetes .
    Hyocholic Acid
  • HY-120596
    PPARδ/γ agonist 1 sodium

    		PPAR Neurological Disease
    PPARδ/γ agonist 1 sodium is a chemically unique and brain penetrant dual PPAR delta/gamma agonist. PPARδ/γ agonist 1 sodium can be used for the research of Alzheimer’s disease .
    PPARδ/γ agonist 1 sodium

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: